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Abstract
Introduction KRAS was one of the earliest human oncogenes to be described and is one of the most commonly mutated 
genes in different human cancers, including colorectal cancer. Despite KRAS mutants being known driver mutations, KRAS 
has proved difficult to target therapeutically, necessitating a comprehensive understanding of the molecular mechanisms 
underlying KRAS-driven cellular transformation.
Objectives To investigate the metabolic signatures associated with single copy mutant KRAS in isogenic human colorectal 
cancer cells and to determine what metabolic pathways are affected.
Methods Using NMR-based metabonomics, we compared wildtype (WT)-KRAS and mutant KRAS effects on cancer cell 
metabolism using metabolic profiling of the parental KRAS G13D/+ HCT116 cell line and its isogenic, derivative cell lines 
KRAS +/– and KRAS G13D/–.
Results Mutation in the KRAS oncogene leads to a general metabolic remodelling to sustain growth and counter stress, 
including alterations in the metabolism of amino acids and enhanced glutathione biosynthesis. Additionally, we show 
that KRASG13D/+ and KRASG13D/− cells have a distinct metabolic profile characterized by dysregulation of TCA cycle, up-
regulation of glycolysis and glutathione metabolism pathway as well as increased glutamine uptake and acetate utilization.
Conclusions Our study showed the effect of a single point mutation in one KRAS allele and KRAS allele loss in an isogenic 
genetic background, hence avoiding confounding genetic factors. Metabolic differences among different KRAS mutations 
might play a role in their different responses to anticancer treatments and hence could be exploited as novel metabolic vul-
nerabilities to develop more effective therapies against oncogenic KRAS.
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1 Introduction
Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras 
or kras2) was one of the earliest human oncogenes to be 
described and is one of the most commonly mutated genes in 
different human cancers, including colorectal cancer (Dinu 
et al., 2014; Tsuchida et al., 2016). Activation of Ras is asso-
ciated with a wide range of biological responses, such as 
cell growth, proliferation, survival, differentiation and tis-
sue morphogenesis, depending on the cell type and stimuli 
(Vartanian et al., 2013). KRAS mutations are associated with 
poor prognosis and resistance to targeted therapies, dem-
onstrating the clinical importance of this gene (Arrington 
et al., 2012).
In addition to the well-documented pro-tumorigenic role 
of mutant Ras alleles, there is some evidence suggesting that 
the wild type copy of Ras can display tumour-suppressor 
effects. Zhang et al. showed that following exposure to car-
cinogenic chemicals, mice harbouring only one copy of wild 
type Kras2 produced larger lung tumors than mice harbour-
ing both wild type alleles (Zhongqiu Zhang et al., 2001). To 
investigate the effect of a single copy mutant KRAS, Varta-
nian et al. analysed the signalling and biological properties 
of a panel of isogenic cancer cell lines (DLD1, HCT116, and 
Hec1A) (Vartanian et al., 2013). They demonstrated that a 
single copy of mutant KRAS results in only modest activa-
tion of downstream signalling pathways involving extracel-
lular signal-regulated kinase (ERK) and AKT. One copy of 
mutant KRAS had a small effect on cell proliferation and 
cell migration, but a greater effect on cell transformation, 
as evaluated by growth in soft agar. Interestingly, elimina-
tion of the wild type KRAS allele led to increased growth 
in soft agar, indicating tumor-suppressive characteristics of 
the wild type KRAS allele under these conditions (Vartanian 
et al., 2013).
Like many oncogenes, mutant KRAS impacts cellular 
metabolism and these effects might underlie some of the 
biological effects of wild type and mutant KRAS outlined 
above.
Metabonomics (Everett et al., 2019; Lindon et al., 2000) 
is a novel field in systems biology that produces disease-rel-
evant molecular information downstream of the genome and 
proteome and has shown early promise in cancer research. 
We recently demonstrated the power of metabonomics to 
define the specific profiles of human SW48 colorectal can-
cer cells carrying different KRAS mutations in codons 12, 
13, 61 and 146 compared with their wild-type counterpart 
(Varshavi et al., 2020).
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In this study, we applied NMR-based metabonomics to 
obtain an understanding of metabolic dysregulation driven 
by common KRAS mutations and also studied the effects 
of single copy mutant KRAS on the cellular metabolic pro-
file. Specifically, we compared the metabolic profiles of 
parental HCT116 KRAS G13D/+ (a cell line isolated from a 
patient with colorectal cancer in which glycine (G) 13 is 
mutated to aspartate (D)) and its isogenic derivative cell 
lines: KRAS +/– and KRAS G13D/–. In the cell line KRAS 
+/–, the mutated KRAS allele is deleted and the WT allele 
remains, whereas in KRAS G13D/– the WT KRAS allele is 
deleted and the G13D mutant allele remains. These iso-
genic cell lines share the same genetic background, dif-
fering only by the mutational status of the KRAS gene and 
therefore allowed study of the metabolic functions of nor-
mal or mutant KRAS proteins and in particular, allowed 
us to determine the effects of the loss of an allele of the 
cell line metabolic profile, something that had not been 
possible in our previous studies (Varshavi et al., 2020).
2  Experimental
2.1  Cell culture and harvesting method
HCT116 colorectal carcinoma isogenic cell lines were 
obtained from Horizon Discovery Ltd (Cambridge, UK) 
and maintained at 37 °C with 5%  CO2. Cell lines were 
generated using the Recombinant Adeno-Associated Virus 
(rAAV) based gene editing platform and were all validated 
by genotyping—gDNA and cDNA. The study was con-
ducted in vitro with the cells transiently growing as sphe-
roids in low adherence flasks, cultured and harvested as 
recently described using five biological replicates (Var-
shavi et al., 2020).
2.2  Metabolite extraction of HCT116 cell lines
Intracellular metabolites were extracted as previously 
described with some modifications (Dettmer et al., 2011). 
800 μl of chilled MeOH/H2O (− 20 °C, 80:20(v/v)) was 
added to the frozen cell pellet, homogenized for 1 min 
using Pellet pestles (Sigma-Aldrich, UK). The sample was 
centrifuged at 4 °C and 7000×g for 5 min and the superna-
tant was collected into a new Eppendorf tube. The pellet 
was re-extracted three times with 400 μl cold methanol/
water (− 20 °C, 80:20 (v/v)) to produce 2 ml of extract. 
The supernatants were combined, dried under a gentle flow 
of  N2 gas and stored at -80° C until dissolution for NMR 
analysis.
2.3  Cell extract sample preparation and NMR 
acquisition
Samples were prepared, acquired, processed and analysed 
as described previously (Benjamini, 2010; Varshavi et al., 
2018, 2020; Veselkov et al., 2014). Two-dimensional NMR 
experiments were carried out for selected samples to aid/
confirm the identities of the metabolites (Dona et al., 2016). 
Details for HCT116 KRAS G13D/− are in Supplementary 
Table 1. Metabolites were identified at MSI level 2 (Sumner 
et al., 2007) and as previously described and using published 
methods (Dona et al., 2016; Everett, 2015; Varshavi et al., 
2020) (Table 1, Supplementary Table 2).
2.4  Multivariate analysis of HCT116 cell line 
extracts
PCA was conducted on all samples to establish any obvi-
ous outliers in the data and to determine any between group 
differences. In order to maximize the separation between 
classes, NMR data were also subject to a supervised 
dimension-reduction technique, maximum margin crite-
rion (MMC, Supplementary Fig. 1) (Veselkov et al., 2014). 
Leave-one-out cross-validation with the quadratic as a clas-
sifier was applied to check the validity of the MMC model 
(Supplementary Fig. 2). To determine metabolites respon-
sible for the class separation, one-way ANOVA was applied 
with a false discovery rate (FDR) of 0.1 i.e. 10%, in order to 
account for multiple hypothesis testing.
3  Results
3.1  Metabonomics analysis of HCT116 cell line 
extracts expressing WT or G13D mutant KRAS
A representative 1H NMR spectrum from an HCT116 KRAS 
G13D/− extract is shown in Fig. 1 (a, b). PCA of the three 
genotypes showed high degrees of reproducibility among 
the biological replicates for each group. Moreover, PCA 
demonstrated a clear discrimination between all three geno-
types: KRAS G13D/+, KRAS ± and KRAS G13D/− as shown in 
Fig. 2. Supervised maximum margin criterion (MMC) analy-
sis gave correct classification rates of 100% for the models 
constructed between all classes.
Figure 3 and Supplementary Figs. 3 and 4 show repre-
sentative ANOVAs built between genotypes (KRAS G13D/+ 
vs KRAS ±), (KRAS G13D/− vs KRAS ±) and (KRAS G13D/+ 
vs KRAS G13D/−) respectively. Table 1 and Supplementary 
Table 3 provide a list of statistically significant metabo-
lites and their relative fold-changes between genotypes. 
To further understand the biological significance of the 
metabolite changes in the KRAS mutant clones, we used 
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enrichment analysis (EA) tools in MetaboAnalyst to link 
metabolites to metabolic pathways (Fig. 4). In both KRAS 
G13D/− and KRAS G13D/+ cells, ammonia recycling, glu-
tathione metabolism, glycine and serine metabolism path-
ways and glutamate metabolism were over-represented.
KRAS G13D/+ and KRAS G13D/− cells showed elevated 
levels of valine, isoleucine, leucine, threonine, alanine, 
proline, glutamate, glutathione, aspartate, asparagine, 
creatine, taurine and serine relative to HCT116 cell lines 
harbouring only one WT KRAS allele (KRAS ±).
Compared to KRAS ± cells, KRAS G13D/− cells also 
exhibited higher levels of lactate, glutamine, succinate, 
choline, betaine, inosine and adenosine 5′-monophosphate 
(AMP) and lower levels of acetate, creatine phosphate 
and adenosine 5′-triphosphate ATP while KRAS G13D/+ 
cells displayed increased levels of glycine and ATP and 
decreased levels of myo-inositol.
KRAS G13D/− cells showed higher levels of lactate, suc-
cinate, choline, betaine, glutamine, glutathione, creatine 
and inosine, and lower levels of serine, threonine, glycine, 
acetate, creatine phosphate, phosphocholine, myo-inositol 
and ATP relative to KRAS G13D/+ cells.
4  Discussion
Altered metabolism has been recently recognized as one 
of the hallmarks of cancer cells, allowing metabonomics 
to be widely used as a powerful tool to identify diagnostic 
cancer biomarkers and new therapeutic targets (Spratlin 
et al., 2009; Varshavi et al., 2020; Vermeersch & Styc-
zynski, 2013). Oncogenic KRAS is one of the genes that 
is frequently mutated in colorectal cancer, and mutant 
KRAS is associated with poor prognosis and resistance 
Table 1  Summary of the most significant metabolites differentiating between the genotypes KRAS G13D/+ vs KRAS±, KRAS G13D/− vs KRAS± and 
KRAS G13D/− vs KRAS G13D/+ (p value adjusted for FDR of 0.1)
Footnotes: # Absent in KRASG13D/−  ♦ Absent in KRAS±  Absent in KRASG13D/+







Isoleucine 0.943 (t), 1.01 (d), 3.675 (d) ↑ ↑ –
Valine 0.996 (d), 1.046 (d), 3.615 (d) ↑ ↑ –
Leucine 0.961 (d), 0.972 (d), 1.691 (m), 1.720 (m), 1.748 (m), 3.737(dd) ↑ ↑ –
Lactate 1.331 (d), 4.113 (q) – ↑ ↑
Threonine 1.335 (d), 3.591 (d) ↑ ↑ ↓
Alanine 1.48 (d), 3.787 (q) ↑ ↑ –
Acetate 1.919 (s) – ↓ ↓
Proline 2.011 (m), 2.073 (m), 2.359 (m), 4.14 (dd) ↑ ↑ –
Glutamate 2.059 (m), 2.140 (m), 2.355 (m), 3.761 (dd) ↑ ↑ –
Glutamine 2.145 (m), 2.46 (m), 3.783 (t) – ↑ ↑
Glutathione 2.171 (m), 2.560 (m), 2.935 (dd), 2.980 (dd), 3.782 (m), 4.572 (dd) ↑ ↑ ↑
Succinate 2.406 (s) – ↑ ↑
Aspartate 2.684 (dd), 2.816 (dd), 3.902 (dd) ↑ ↑ –
Asparagine 2.85 (dd), 2.88 (dd) ↑ ↑ –
Creatine 3.041 (s) ↑ ↑ ↑
Creatine phosphate 3.045 (s), 3.95 (s) – ↓ ↓#
Choline 3.207 (s) – ↑ ↑
Phosphocholine 3.224 (s), 3.597 (s) – – ↓
Betaine 3.269 (s) – ↑ ↑
Taurine 3.27 (t), 3.42 (t) ↑ ↑ –
Myo-inositol 3.284 (t), 3.54 (dd), 3.62 (dd), 4.067 (t) ↓ – ↑
Glycine 3.562 (s) ↑ – ↓
Serine 3.848 (dd), 3.950 (dd), 3.995 (dd) ↑ ↑ ↓
Inosine 3.845 (dd), 3.915 (dd), 4.282 (m), 4.442 (dd), 4.787 (t), 6.107 (dd), 8. 
241 (s), 8.348 (s)
– ↑♦  
ATP 8.54 (s), 8.27 (s) ↑ ↓ ↓
AMP 8.61 (s), 8.27 (s) – ↑ ↑
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to therapeutics (Mayers et  al., 2016). About 80% of 
KRAS mutations are heterozygous (Hartman et al., 2012). 
However, in many types of cancer the remaining wild-
type KRAS gene can be lost during tumour progression. 
Therefore, wild-type KRAS might serve as a tumour-
suppressor gene in the presence of mutant KRAS (Luo 
et al., 2014; To et al., 2013; Zhang et al., 2001; Zhongqiu 
Hartman et al., 2012). Mutant KRAS is a known driver 
a
Fig. 1  a The aliphatic region of the 600  MHz 1H NMR spectrum 
from an HCT116 KRAS G13D/− extract. Numbers indicate signals cor-
responding to individual metabolites. 1. leucine; 2. valine; 3. lactate 
and threonine; 4. alanine; 5. acetate; 6. glutamate; 7. succinate; 8. 
glutamine; 9. glutathione; 10. aspartate; 11. asparagine; 12. creatine; 
13. O-phosphocholine; 14. taurine; 15. myo-inositol; 16. glycine. 
b The aromatic region of the 600 MHz 1H NMR spectrum from an 
HCT116 KRAS G13D/− extract. Numbers indicate signals correspond-
ing to individual metabolites. 18. uridine; 19. NAD; 20. tyrosine; 21. 
phenylalanine; 22. inosine; 23. ATP; 24. AMP
 D. Varshavi et al.
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Component
VS
Fig. 2  a PCA score plot of the 600 MHz 1H NMR spectra of extracts 
of HCT116 cells, b superimposed NMR spectra of cells, with the 
same colour coding as in the PCA plot; c ‘heat map display of the 
600 MHz 1H NMR spectra from 0.8 to 10.0 ppm of KRAS G13D/− (top 
5 strips), KRAS G13D/+middle 5 strips) and KRAS ± (bottom 5 strips). 
Red and blue elements in the spectra indicate NMR signals that are 
more intense, or less intense, respectively, than the median signal 
intensity for all the samples
Fig. 3  At bottom a ‘heat map display of the 600 MHz 1H NMR spec-
tra of KRAS G13D/+ (top 5 strips) vs the corresponding spectra of 
KRAS± (bottom 5 strips). Red and blue elements in the spectra indi-
cate NMR signals that are more intense, or less intense, respectively, 
than the median signal intensity for all the samples. At top, the cor-
responding ANOVA plot, showing positive peaks for those metabolite 
signals that are more intense in KRAS G13D/+, and negative peaks for 
those metabolite signals that are less intense. The signals are colour 
coded by the p value adjusted for FDR of 0.1
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mutation for cancer development and progression, mak-
ing KRAS mutant proteins good candidates for therapeu-
tic development. Yet, until recently, KRAS mutants have 
proved difficult to target with small molecules, fuelling 
interest in targets upstream and downstream of KRAS 
for drug discovery. Understanding the metabolic conse-
quences of WT KRAS allele loss might provide additional 
information in identifying key vulnerabilities in tumours 
with mutant KRAS.
In the current study, we applied an exploratory, untar-
geted, NMR-based metabonomics approach to obtain an 
understanding of metabolic dysregulation driven by a 
common human KRAS oncogenic mutation, G13D. The 
use of isogenic cell lines in this study also afforded us 
window into the effects of single copy mutant KRAS on 
metabolic alteration.
To this end, we compared the metabolic profiles of the 
parental KRAS G13D/+ (parental line isolated from a colo-
rectal cancer patient in which glycine (G) 13 is mutated to 
aspartate (D)) and its isogenic derivative cell lines KRAS 
+/– and KRAS G13D/– in human colon cancer cells (HCT116). 
In the cell line KRAS +/–, the mutated KRAS allele is deleted 
and the WT one remains, whereas in KRAS G13D/– the WT 
KRAS allele is deleted and the G13D mutated one remains.
PCA analysis (Fig. 2) showed a clear discrimination 
not only between mutant-containing (KRAS G13D/+, KRAS 
G13D/–) and wild-type-containing (KRAS +/–) KRAS, but also 
between KRAS G13D/+ and KRAS G13D/–. Interestingly, paren-
tal cell lines (KRAS G13D/+) clustered more closely to mutant 
KRAS-deleted lines (KRAS +/–) than to WT KRAS-deleted 
lines (KRAS G13D/–), indicating that in each isogenic cell 
line the WT KRAS allele has a stronger effect on the overall 
metabolic profile than the mutant allele. The main alterations 
associated with mutant KRAS involved changes in multiple 
metabolic pathways such as glycolysis, TCA, and most sig-
nificantly amino acid pathways (Fig. 5).
The amino acids most commonly consumed at a high rate 
by cancer cells are glutamine and serine (Tsun & Posse-
mato, 2015). The serine levels in HCT116 KRAS G13D/+ or 
KRAS G13D/– cells were significantly higher compared with 
isogenic HCT116 cells containing only a wild-type KRAS 
allele (KRAS +/–).
Serine is a non-essential amino acid that contributes to a 
range of metabolic processes, which are vital for the growth 
and survival of cancer cells, including protein, lipid, nucle-
otide and glutathione biosynthesis, as well as one-carbon 
metabolism (Amelio et al., 2014; Yang & Vousden, 2016). 
Serine can be either taken up from the medium by the trans-
formed cell or be produced from the glycolytic intermedi-
ate 3-phosphoglycerate (3PG). The first step in the serine 
synthesis pathway (SSP) involves the conversion of 3-phos-
phoglycerate to 3-phosphohydroxypyruvate (3PHP) by 
the  NAD+-dependent enzyme 3-phosphoglycerate dehydro-
genase (PHGDH). 3-Hydroxypyruvate can be then transami-
nated to phosphoserine by the enzyme phosphoserine ami-
notransferase (PSAT1), using glutamate as amino donor 
(Amelio et al., 2014; Yang & Vousden, 2016). Serine is sub-
sequently produced from phosphoserine by phosphoserine 
phosphatase (PSPH). PHGDH, the initial enzyme in the SSP, 
is reportedly upregulated in breast cancers and melanomas 
Fig. 4  Metabolic pathway analyses related to the metabolites that 
were discriminating between a KRAS G13D/+ and  KRAS±, b KRAS 
G13D/− and  KRAS± and c KRAS G13D/+ and KRAS G13D/−. The hori-
zontal bars summarize the main metabolite sets identified in this anal-
ysis; the bars are coloured based on their p values and the length is 
based on the fold enrichment
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(Labuschagne et al., 2014; Possemato et al., 2011). However, 
many cancer cells are largely dependent on uptake of exog-
enous serine, as de novo serine synthesis alone cannot sup-
port their proliferation and survival (Jain et al., 2012; Mad-
docks et al., 2013). The enhanced concentrations of serine in 
KRAS G13D/– and KRAS G13D/+ cells relative to KRAS +/– cells 
could, therefore, be due to an increase in serine uptake from 
the medium and/or biosynthesis. Interestingly, lower lev-
els of serine were observed in KRAS G13D/– versus KRAS 
G13D/+ cells. This could be associated with either increased 
consumption or decreased uptake/biosynthesis. The latter is 
more likely, as serine is involved in adenine synthesis, and 
its limited availability can result in a decreased concentra-
tion of ATP in the cell. This is consistent with our observa-
tion, showing lower levels of ATP in KRAS G13D/– cells ver-
sus KRAS G13D/+ and KRAS +/– cells. This hypothesis could 
be tested further by comparison of the serine concentration 
in the culture media across the cell lines.
Concentrations of glutamine in KRAS G13D/+ and KRAS 
+/– cells were comparable but increased in KRAS G13D/– cells 
relative to KRAS +/– and KRAS G13D/+ cells. The increased 
levels of glutamine in KRAS G13D/– cells could indicate that 
the WT KRAS-deleted isogenic cell lines are more dependent 
on glutamine and hence they take it up at a high rate.
Glutamine is a “conditionally essential” amino acid that 
is synthesized sufficiently under normal  circumstances 
but becomes essential during proliferation. KRAS-mutant 
cells can be particularly dependent on glutamine as a car-
bon source to fuel the TCA cycle and as a nitrogen source 
for nucleotide, hexosamine and nonessential amino acid 
(NEAA) biosynthesis (Toda et  al., 2016). Glutamine is 
transported into the cell through one of many transporters, 
such as the neutral amino acid transporter (ASCT2) (Scopel-
liti et al., 2018). Once imported into the cells, glutamine is 
converted to glutamate by glutaminase (GLS) in the mito-
chondria (Chendong Yang et al., 2014). In this study, higher 
intracellular concentrations of glutamate were observed in 
KRAS mutant cells (KRAS G13D/+, KRAS G13D/–) relative to 
wild-type-containing cells (KRAS +/–), indicating increased 
glutaminolysis.
Fig. 5  An overview of metabolic pathways altered in HCT116 cell 
line expressing the WT or the G13D mutant KRAS. Yellow boxes rep-
resent deregulated metabolites. The direction of the arrows shows the 
regulation direction of metabolites; the red arrows represent metabo-
lites in KRAS G13D/− compared to KRAS ±; the green arrows repre-
sent metabolites in KRAS G13D/+ compared to KRAS ±, the blue arrows 
represent metabolites in KRAS G13D/− compared to KRAS G13D/+. 
 indicates that the metabolite is only present or only absent 
in KRAS G13D/− compared to KRAS G13D/+ respectively.  indi-
cates that the metabolite is only present and absent in KRAS G13D/− 
compared to KRAS ± respectively: 3PG (3-phosphoglycerate), AMP 
(Adenosine monophosphate), ADP (Adenosine diphosphate), ATP 
(Adenosine triphosphate), α- KG (α-ketoglutarate), DMG (Dimeth-
ylglycine), GSH (Glutathione), GTP (Guanosine-5'-triphosphate), 
HIF-1α (Hypoxia-inducible factor 1-alpha), NADP (Nicotinamide 
adenine dinucleotide phosphate), NADPH (Nicotinamide adenine 
dinucleotide phosphate), PCho (Phosphocholine), PHD (Prolyl-
hydroxylase), ROS (Reactive Oxygen Species), UDP-GlcNAc (Uri-
dine diphosphate N-acetylglucosamine)
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Glutamate can subsequently be conver ted to 
α-ketoglutarate by glutamate dehydrogenase 1 (GLUD1) 
where it can fuel the TCA cycle or be converted to non-
essential amino acids such as aspartate and alanine by 
transaminases, including glutamate–oxaloacetate transami-
nase (GOT) and glutamate–pyruvate transaminase (GPT), 
respectively. Glutamate can also contribute to the synthesis 
of proline and glutathione (Liu et al., 2012).
In the current study, KRAS G13D/+ and KRAS G13D/– cells 
showed increased levels of metabolites associated with 
the glutamate synthase cycle including alanine, aspartate, 
asparagine, proline and glutathione when compared to KRAS 
+/– cells.
Elevated levels of aspartate and asparagine in mutant 
KRAS cells relative to KRAS +/– is consistent with other 
studies reporting that oncogenic KRAS shifts glutamine 
metabolism toward aspartate synthesis (Ahn & Metallo, 
2015; Lyssiotis et al., 2013; Son et al., 2013b). Aspartate is 
synthesised by transferring the α-amino group on glutamate 
to the α-keto group of oxaloacetate. This metabolic altera-
tion is thought to have an important role in regeneration of 
NADPH and NAD to maintaining redox balance in addition 
to glycolysis (Son et al., 2013a). Additionally, aspartate and 
glutamine are the precursors for asparagine. Asparagine is 
involved in the regulation of the cellular adaptation to deple-
tion of glutamine and other nonessential amino acids, as well 
as suppression of apoptosis induced by glutamine depletion 
(Zhang et al., 2014).
Glutathione (GSH) levels were also increased in mutant 
KRAS cells compared to their WT, isogenic counterpart 
(KRAS +/–). A higher level of glutathione was also evident 
in KRAS G13D/– relative to KRAS G13D/+ cells. In agreement 
with our findings, a recent study (Kerr et al., 2016) found 
that KRAS mutation and copy number gain is associated 
with up-regulation of glutathione metabolism. Glutathione 
is a tripeptide (consisting of glutamate, cysteine and gly-
cine) that is involved in cellular protection against reactive 
oxygen species (ROS) and reactive nitrogen (RNS) species 
(Aquilano et al., 2014). GSH deregulation has been reported 
in many human cancers (Calvert et al., 1998; Estrela et al., 
2006; Obrador et al., 2002), possibly because GSH is protec-
tive against oxidative damage (Ortega et al., 2010), stress-
induced apoptosis (Franco et al., 2009) and multidrug and 
radiation resistance (Arrick & Nathan, 1984; Estrela et al., 
1995; Meister, 1991; Mitchell & Russo, 1987).
KRAS G13D/+ and KRAS G13D/– cells also exhibited higher 
concentrations of proline relative to KRAS +/– cells. Proline 
is an α-amino acid that is derived from glutamate via the 
intermediate pyrroline-5-carboxylate (P5C). P5C is subse-
quently converted to proline by the NAD (P) H-dependent 
enzyme pyrroline-5-carboxylate reductase (PYCR), which is 
present in three isoforms: PYCR1, PYCR2 and PYCRL. Up-
regulation of mitochondrial PYCR1 and PYCR2 is observed 
in a number of cancer types, such as prostate cancer and 
lymphoma (Ahn & Metallo, 2015; De Ingeniis et al., 2012; 
Ernst et al., 2002). In addition to biosynthesis, proline catab-
olism is reportedly down-regulated in a number of tumour 
types. The first step of proline catabolism is catalysed by 
proline oxidase, which is proposed as a novel mitochondrial 
tumour suppressor in human cancers (Liu et al., 2012). In 
their paper, Liu and colleagues propose proline metabolism 
as a crucial link in the reprogramming of glutamine and 
glucose metabolism during tumorigenesis. Therefore, the 
enzymes involved in proline biosynthesis could provide 
novel targets for cancer therapy.
In our study, we have observed metabolic variation not 
only between KRAS mutant (KRAS G13D/+, KRAS G13D/–) 
cells and wild-type (KRAS +/–) cells, but also between 
KRAS G13D/+ and KRAS G13D/– cells. Interestingly, KRAS 
G13D/– showed higher levels of succinate relative to both 
KRAS +/– and KRAS G13D/+. Accumulation of succinate is 
associated with the inhibition of prolyl hydroxylases. One 
of the consequences of this inhibition is the stabilization 
of the transcription factor hypoxia-inducible factor 1-alpha 
(HIF-1α) and the generation of a pseudo-hypoxic response 
reducing oxidative phosphorylation and promoting glycoly-
sis (Selak et al. 2005; Tavares et al., 2015). Stabilisation of 
HIF1α results in the increased expression of lactate dehy-
drogenase A (LDHA), which increases the conversion of 
pyruvate to lactate, and the expression of pyruvate dehydro-
genase kinase 1 (PDK1), which inhibits pyruvate dehydroge-
nase (PDH) and decreases mitochondrial oxidation of pyru-
vate to acetyl coenzyme A (acetyl-CoA) (Kim et al., 2006; 
Schulze & Harris, 2012; Zhao et al., 2014). One hypothesis 
is that under metabolic stress (hypoxia or nutrient depriva-
tion), acetyl-CoA production can be compensated by acetyl-
CoA synthase 2 (ACCS2), which converts acetate to acetyl-
CoA using ATP to drive the net reaction (Kamphorst et al., 
2014; Schug et al., 2015). Our results showing increased 
levels of succinate, lactate and AMP and decreased con-
centrations of acetate in KRAS G13D/– cells relative to KRAS 
+/– and KRAS G13D/+ cells support these observations and 
indicate that the KRAS G13D mutation could impact HIF1α 
function in the absence of the WT KRAS allele.
In addition, as HIF-1α can also actively repress mitochon-
drial aerobic metabolism through PDK1 (Papandreou et al., 
2006), interruption of the TCA cycle could explain lower 
levels of ATP in KRAS G13D/− cells compared with KRAS 
G13D/+ and KRAS ± cells. Interestingly, we also observed 
increased levels of creatine and depletion of phosphocre-
atine in KRAS G13D/− cells relative to KRAS G13D/+ and KRAS 
± cells. This could indicate that in low ATP states, phos-
phocreatine can be used as a rapidly mobilisable reserve of 
high-energy phosphates to sustain the energetic requirements 
of cancer cells.
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5  Conclusion
Overall, our data provide further insights into nutrient use 
and the regulation of metabolic pathways driven by onco-
genic KRAS. In this study, we have used a robust isogenic 
system to study the role of a single point mutation in one 
KRAS allele in an isogenic genetic background, hence avoid-
ing confounding genetic factors.
We have demonstrated that the KRASG13D oncogene is 
associated with general metabolic reprogramming to sup-
port growth and counter stress, including alterations in 
the metabolism of amino acids and enhanced glutathione 
biosynthesis. Additionally, we show that KRASG13D/+ and 
KRASG13D/− cells have distinct metabolic profiles charac-
terized by dysregulation of and changes in the TCA cycle, 
the glycolysis and glutathione metabolism pathways, as 
well as in glutamine, acetate and phosphocreatine. The 
metabolic adaptation driven by the loss of the KRAS WT 
allele that we have initially described in this paper could 
contribute to differential responses to anticancer treat-
ments and/or reveal pathways that might be exploited for 
therapeutic intervention.
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